


UNBUNDLING GENE PRODUCTS FOR RARE DISEASES FROM CURRENT REIMBURSEMENTS TO HOSPITALS (SF4058/HF3664)

New policies that support the rare disease community in Minnesota: What you should know

The Minnesota Legislature enacted legislation to enhance the reimbursement process for bio-logical products used in cell or gene therapy to treat rare diseases. These bills authorize the Commissioner of Human Services to provide separate reimbursement for these biological products when administered in an inpatient hospital setting.



LEARN MORE For more information on RDAC policy goals, click here.

